IOVA

2.27

4.13% 0.09

Handel nachbörslich: 2.30 0.03 +1.32%

Iovance Biotherapeutics Inc (IOVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt IOVA? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.18

Offen:

$2.2

24-Stunden-Volumen:

15.13M

Relative Volume:

1.02

Marktkapitalisierung:

$821.41M

Einnahmen:

$241.53M

Nettoeinkommen (Verlust:

$-389.92M

KGV:

-1.8455

EPS:

-1.23

Netto-Cashflow:

$-323.54M

1W Leistung:

+2.71%

1M Leistung:

-4.62%

6M Leistung:

-20.35%

1J Leistung:

-76.65%

1-Tages-Spanne:

$2.18

$2.34

1-Wochen-Bereich:

$2.09

$2.38

52-Wochen-Spanne:

$1.6385

$12.51

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Firmenname

Iovance Biotherapeutics Inc

Sektor

Healthcare (1141)

Branche

Biotechnology (639)

Telefon

(650) 260-7120

Adresse

825 INDUSTRIAL ROAD, SAN CARLOS

Mitarbeiter

838

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

IOVA's Discussions on Twitter

Vergleichen Sie IOVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IOVA Iovance Biotherapeutics Inc	2.27	788.84M	241.53M	-389.92M	-323.54M	-1.23
VRTX Vertex Pharmaceuticals Inc	421.15	105.19B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	450.68	60.24B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	563.86	61.82B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	798.94	49.09B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	351.09	37.52B	4.56B	-176.77M	225.30M	-1.7177

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-15	Herabstufung	Goldman	Neutral → Sell
2025-05-16	Herabstufung	UBS	Buy → Neutral
2025-05-12	Herabstufung	Truist	Buy → Hold
2025-05-09	Herabstufung	Citizens JMP	Mkt Outperform → Mkt Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-07-29	Herabstufung	Piper Sandler	Overweight → Neutral
2023-11-20	Eingeleitet	Goldman	Buy
2023-09-18	Bestätigt	Barclays	Overweight
2023-05-30	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-27	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-09	Herabstufung	Goldman	Buy → Neutral
2022-10-31	Eingeleitet	Guggenheim	Neutral
2022-08-18	Fortgesetzt	Wells Fargo	Equal Weight
2022-01-28	Hochstufung	Stifel	Hold → Buy
2021-12-07	Fortgesetzt	Cowen	Outperform
2021-06-10	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2021-05-20	Herabstufung	Piper Sandler	Overweight → Neutral
2021-05-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2021-05-19	Herabstufung	Stifel	Buy → Hold
2021-05-03	Eingeleitet	Truist	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2021-03-08	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-12-15	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-10-06	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-22	Eingeleitet	Mizuho	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-02-26	Bestätigt	H.C. Wainwright	Buy
2020-02-26	Bestätigt	Oppenheimer	Outperform
2019-12-18	Eingeleitet	JMP Securities	Mkt Outperform
2019-10-01	Eingeleitet	Stifel	Buy
2019-04-29	Eingeleitet	Piper Jaffray	Overweight
2019-02-28	Bestätigt	Chardan Capital Markets	Buy
2019-02-07	Eingeleitet	Robert W. Baird	Outperform
2018-12-31	Fortgesetzt	B. Riley FBR	Buy
2018-07-06	Bestätigt	Chardan Capital Markets	Buy
2018-04-10	Hochstufung	B. Riley FBR, Inc.	Neutral → Buy
2018-03-13	Bestätigt	B. Riley FBR, Inc.	Neutral
2018-02-23	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-01-25	Bestätigt	H.C. Wainwright	Buy
2017-11-01	Bestätigt	B. Riley FBR, Inc.	Buy

Alle ansehen

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

03:08 AM

IOVANCE (IOVA) ALERT: Bragar Eagel & Squire, P.C. Continues - GlobeNewswire

03:08 AM

01:15 AM

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 6.7%What's Next? - MarketBeat

01:15 AM

Oct 06, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 4.5%Should You Sell? - MarketBeat

Oct 06, 2025

Iovance Biotherapeutics (IOVA): Examining Valuation as Share Price Momentum Stalls - Yahoo Finance

Oct 06, 2025

How supply shortages influence Iovance Biotherapeutics Inc. (2LB) stock2025 Price Momentum & Growth Oriented Trade Recommendations - newser.com

Oct 06, 2025

Will Iovance Biotherapeutics Inc. rebound enough to break evenAnalyst Downgrade & Safe Entry Trade Signal Reports - newser.com

Oct 06, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock fits value portfoliosChart Signals & Verified Technical Signals - newser.com

Oct 06, 2025

Will Iovance Biotherapeutics Inc. (2LB) stock announce special dividendMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com

Oct 06, 2025

Oct 05, 2025

What the Recent 11% Surge Means for Iovance Biotherapeutics Stock in 2025 - Sahm

Oct 05, 2025

Why Iovance Biotherapeutics Inc. (2LB) stock signals breakout potentialJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com

Oct 05, 2025

Oct 04, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Oct 04, 2025

Oct 03, 2025

Iovance Biotherapeutics (IOVA) Valuation in Focus After Recent Share Price Gains - Sahm

Oct 03, 2025

How Iovance Biotherapeutics Inc. stock performs during Fed tightening cyclesShort Setup & Capital Efficient Trade Techniques - newser.com

Oct 03, 2025

Is Iovance Biotherapeutics Inc. (2LB) stock positioned for digital growth eraMarket Volume Summary & AI Enhanced Trading Alerts - newser.com

Oct 03, 2025

Oct 02, 2025

Analyzing Iovance Biotherapeutics Inc. with multi timeframe chartsJuly 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com

Oct 02, 2025

Oct 01, 2025

Volatility clustering patterns for Iovance Biotherapeutics Inc.Quarterly Market Review & Capital Efficiency Focused Strategies - newser.com

Oct 01, 2025

Sep 30, 2025

Iovance Biotherapeutics Inc Stock Analysis and ForecastBull Market Opportunities & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in

Sep 30, 2025

What analysts say about Iovance Biotherapeutics Inc stockMoving Average Crossovers & High Return Trading Portfolio - earlytimes.in

Sep 30, 2025

Sep 28, 2025

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Sep 28, 2025

Sep 27, 2025

Is Iovance Biotherapeutics Inc 2LB a good long term investmentStock Market Trends & Access Free Tools and Start Investing - Early Times

Sep 27, 2025

Is Iovance Biotherapeutics Inc a good long term investmentCapital Gains Strategies & Free Hedging Tactics for Volatile Markets - Early Times

Sep 27, 2025

Iovance Biotherapeutics Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo

Sep 27, 2025

Sep 26, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Share Price Passes Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat

Sep 26, 2025

Sep 25, 2025

Healthcare's Convergence Accelerates as Aging Demographics Meet Breakthrough Therapies - Baystreet.ca

Sep 25, 2025

Sep 21, 2025

Assessing Iovance Biotherapeutics (IOVA) Valuation Following Key Strategic Updates and Growth Plans - Sahm

Sep 21, 2025

Revenue Check: Can Iovance Biotherapeutics Inc deliver consistent EPS growthTrade Entry Report & AI Enhanced Execution Alerts - خودرو بانک

Sep 21, 2025

Sep 20, 2025